Sequentia Biotech is a technology company.
Sequentia Biotech specializes in bioinformatics and biotechnology solutions, offering services in health, agriculture, and industrial applications.
Sequentia Biotech has raised $11.0M across 1 funding round.
Sequentia Biotech has raised $11.0M in total across 1 funding round.
Sequentia Biotech has raised $11.0M in total across 1 funding round.
Sequentia Biotech's investors include Plug & Play Ventures, Seventure Partners.
Sequentia Biotech is a Barcelona-based bioinformatics company specializing in transforming complex omics data—such as genomics, transcriptomics, metagenomics, and epigenomics—into actionable knowledge for clinical, industrial, agricultural, and environmental applications. Their product offerings include bioinformatics cloud software (SaaS), custom software development, and consulting services that serve researchers, healthcare, pharma, agriculture, and industry clients worldwide. The company addresses the challenge of interpreting vast biological data to enable breakthroughs in health, sustainable agriculture, and industrial processes, boasting over 10 years of experience, more than 500 projects completed, and a global client base spanning 65 countries[1][2][4].
Founded in 2013 by two scientists with strong backgrounds in plant biotechnology and bioinformatics—Walter Sanseverino (CEO) and Riccardo Aiese Cigliano (CSO)—Sequentia Biotech emerged from their expertise in genomics and epigenomics. The idea originated from the need to make omics data more accessible and interpretable, leading to early traction through scientific publications in high-impact journals like Nature and Science, and recognition in national and European innovation awards. Their continuous R&D focus and customer-centric approach have propelled them to become a top digital healthcare and RNA-focused company globally[2][5].
Sequentia Biotech rides the wave of the growing importance of omics sciences and bioinformatics in precision medicine, sustainable agriculture, and industrial biotechnology. The timing is critical as advances in sequencing technologies generate massive datasets requiring sophisticated computational tools to unlock their potential. Market forces such as increasing demand for personalized healthcare, sustainable food production, and bio-based industrial processes favor companies that can translate omics data into actionable insights. Sequentia’s solutions help democratize access to bioinformatics, enabling researchers and industries to accelerate innovation and improve outcomes, thereby influencing the broader ecosystem of digital health and life sciences[1][4].
Looking ahead, Sequentia Biotech is poised to expand its influence by enhancing its bioinformatics platforms with AI and machine learning to further improve data interpretation speed and accuracy. Trends such as multi-omics integration, personalized medicine, and sustainable biotechnology will shape their growth trajectory. Their continued focus on R&D and global partnerships will likely strengthen their leadership in the omics bioinformatics space, making bioinformatics more accessible and impactful across sectors. This evolution ties back to their founding vision of harnessing omics sciences to benefit society broadly, positioning Sequentia as a key enabler in the future of life sciences innovation[1][2][4].
Sequentia Biotech has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Series A in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $11.0M Series A | Plug & Play Ventures, Seventure Partners |